Search results
Novartis Kesimpta® six-year efficacy data show substantial benefits in recently diagnosed...
WDTN-TV 2 Dayton· 7 days agoContinuous Kesimpta® treatment for up to six years showed sustained efficacy in recently diagnosed (≤3 years) treatment-naïve people living with relapsing multiple sclerosis ...
Novartis (NVS) Q1 Earnings, Sales Beat, Guidance Raised
Zacks via Yahoo Finance· 16 hours agoThe year-over-year growth was driven by an increase in sales. Revenues of $11.8 billion climbed 10%...
Novartis Ag (NVS) Q1 2024 Earnings Call Transcript
Motley Fool via Yahoo Finance· 14 hours agoNow moving to Slide 5. Now our growth in the quarter was broad based, and we had strong contributions from many of our key growth drivers, including...
The Zacks Analyst Blog Highlights Novartis, American Express, ConocoPhillips, Netflix and...
Zacks via Yahoo Finance· 16 hours agoThe company's efforts to restructure its business are encouraging. With the separation of Sandoz, it...
Novartis lifts guidance after Q1 results beat expectations
Reuters· 23 hours agoIt has previously predicted that adjusted operating income would increase by a "high single-digit"...
Novartis (NVS) to Report Q1 Earnings: What to Expect?
Zacks via Yahoo Finance· 5 days agoNVS’ first-quarter sales are likely to have been boosted by Kesimpta, Entresto, Kisqali and...
Top Analyst Reports for Novartis, American Express & ConocoPhillips
Zacks via Yahoo Finance· 1 day agoToday's Research Daily features new research reports on 16 major stocks, including Novartis AG...
Novartis raises guidance after beating Q1 expectations By Reuters
Investing.com· 24 hours agoFRANKFURT (Reuters) -Swiss drugmaker Novartis (LON:0QLR) raised its full-year guidance on wider use...